Although some studies have validated reference genes for the accurate quantification of gene expression in glioma clinical samples, including TBP and HPRT1, 14-3-3 protein zeta/delta (YWHAZ), and 60S ribosomal protein L13a (RPL13A) [17,18,19], the reference genes found and reported in these studies are different. This evidence concerns the gene RPL13A and central nervous system cancer.